Drug Target Review rounds up some of the latest developments in materials developed for medical applications, including hydrogels, implants and more.
List view / Grid view
Research & Development (R&D)
Filter the results
A group of researchers has developed a nanotechnology with a single bristle controlled through electron microscopy that can clean surfaces.
Experiments testing the artificial cardiac patch in pigs and rats showed the patch can reduce scarring and improve cardiac function after a heart attack.
A partnership between Imperial College London and CPI will enable the two organisations to translate research into products and services for pharma.
A report states that three quarters of the roughly 230 nanopharmaceuticals in clinical development are for use as targeted cancer therapeutics.
A letter from the CEO of Gilead reveals how the company plans to scale up production of remdesivir in light of the COVID-19 pandemic.
Researchers found that the combination of lopinavir-ritonavir HIV antivirals led to rapid symptom improvement in COVID-19 patients.
In the face of the coronavirus pandemic, restrictions and extreme situations may require changes to ongoing or upcoming clinical trials. These are the key recommendations from the EC, MHRA and FDA.
A new treatment called APR-OD031 has been given Orphan Drug Designation (ODD) by the FDA, for the treatment of phenylketonuria.
A pilot trial of convalescent plasma therapy in 10 severe COVID-19 patients has shown it may be a safe and promising therapeutic option.
The European Medicines Agency has released recommendations about which patients could benefit from remdesivir and the possible criteria for compassionate use of the drug.
Researchers have used triglyceride fatty acids to develop an oral formulation for drugs that are usually injected or taken intravenously.
The coalition has been formed to find R&D solutions for low- and middle-income countries to limit the impact of the COVID-19 pandemic in areas with fragile healthcare systems.
Researchers have created a microneedle array that successfully delivered a COVID-19 vaccine to mice, allowing them to produce antibodies against the virus.
The developers of Avigan have increased production and announced a Phase III clinical trial testing its efficacy against COVID-19.